In March, a COVID-19 vaccine was tested in 45 healthy adults in Phase 1 tests administered by the National Institutes of Health and Moderna Inc. On Tuesday night, all study participants were reported to reflect a response from boosting the immune system, allowing entities testing the vaccine to start testing it on 30,000 participants starting July 27, making it the largest study in the world.
The results were taken from the youngest subjects in the study; The results of older adults are currently being analyzed.
“Those early volunteers developed what are called neutralizing antibodies in their bloodstream, key molecules to block infection, at levels comparable to those found in people who survived COVID-19, the research team reported in the New England Journal of Medicine, “reported AP.
Study leader Dr. Lisa Jackson of the Kaiser Permanente Washington Research Institute in Seattle said: “This is an essential element that is needed to move forward with trials that could really determine if the vaccine protects against infection.” “
The study reported in the New England Journal of Medicine that the scientists “conducted an open-label, phase 1, dose-increasing trial that included 45 healthy adults, 18 to 55 years old, who received two vaccines, at 28 days difference … There were 15 participants in each dose group … After the first vaccination, antibody responses were higher with higher doses. After the second vaccination, titres increased. After the second vaccination, Serum neutralizing activity was detected by two methods in all participants evaluated … Requested adverse events that occurred in more than half of the participants included fatigue, chills, headache, myalgia, and pain at the injection site. Systemic adverse events were more common after the second vaccination, particularly at the highest dose, and three participants in the 250 μg dose group reported one or more adverse events gr birds “.
The study concluded: “The mRNA-1273 vaccine induced anti-SARS-CoV-2 immune responses in all participants, and no limiting safety concerns were identified from the trials.”
The prospective vaccine would be administered twice; the second time a month after the first
Dr. William Schaffner of Vanderbilt University Medical Center noted about the mild side effects: “Small price to pay for protection against COVID.” He added that the results obtained from the study were “a good first step” and assumed that the final tests could reveal that the vaccine is ready by 2021, although he warned: “It would be wonderful. But that assumes that everything is working on time.
In mid-May, The Daily Wire reported: “Moderna’s team performed phase 1 tests on eight people, administering each dose of the vaccine and checking whether the vaccine caused recipients to develop natural immunity to the coronavirus. The researchers said that all participants tested positive for antibodies to the coronavirus 15 days after their first dose. “
Dr. Anthony Fauci commented Tuesday that people think “this is a race for a winner. I am cheering on each of them. We need multiple vaccines. We need vaccines for the world, not just for our own country. “He concluded:” No matter how you cut it, this is good news. “
The Daily Wire is one of the fastest growing conservative media companies in the United States and countercultural news, opinion and entertainment media. Gain internal access to The Daily Wire by becoming a member.
